Abstract:Recent studies in Alzheimer’s disease (AD) suggest that tau proteins spread through the brain following neuronal connections. Several mechanisms could be involved in this process: spreading between brain regions that interact strongly (functionally connected); through the pattern of anatomical connections (structural connectivity); or simple diffusion to spatially adjacent regions (Euclidean distance (EC)). We investigated this by modelling the tau‐spreading process on these different networks, and compared the modelled tau‐depositions with tau‐depositions at several stages of the AD continuum as measured with in‐vivo 18F‐flortaucipir PET. We collected 10‐minutes eyes‐closed, whole‐head magnetoencephalography (MEG) recordings from 82 subjects (Table‐1) with and without Aβ‐pathology (CSF‐Aβ42 and/or amyloid‐PET) from the Amsterdam Dementia Cohort. Subjects were classed as controls (subjective cognitive decline (SCD) Aβ‐,n=25), preclinical AD (SCD Aβ+,n=16), mild cognitive impairment (MCI) due to AD (n=16) and probable AD dementia (n=25). Tau propagation was modelled as an epidemic process (susceptible‐infected (SI) model) on structural networks (Exponential Distance Rule (EDR) or EC), or functional networks (corrected‐amplitude envelope correlation (AEC‐c) in alpha (8‐13Hz) and beta (13‐30Hz) bands) derived from source‐reconstructed MEG data. The group‐level control network was used as backbone for the SI‐model to predict tau spread in the next stages of the AD continuum; parameters were tuned to produce an optimum correlation to the group‐specific tau propagation patterns as measured with dynamic 130‐minutes 18F‐flortaucipir PET, according to 50 regions‐of‐interest (ROIs) in an adjusted version of the probabilistic Hammers atlas. Tau propagation was modelled to start from one seed region (ROI14), which was selected based on its reliability to accurately measure tau deposition. The functional network predicted tau‐spread with highest accuracy in the preclinical AD stage (AEC‐c alpha r=0.59; AEC‐c beta r=0.58), followed by the structural network (r=0.45) and simple diffusion (r=0.44), Figure‐1, Figure‐2, Figure‐3. Prediction accuracy declined for the MCI and AD dementia stages (AEC‐c alpha r=0.50 and r=0.33; AEC‐c beta r=0.40 and r=0.37; structural r=0.29 and r=0.25; diffusion r=0.29 and r=0.25, respectively). Using a relatively simple SI‐model we predicted tau propagation in preclinical AD with an accuracy of approximately 60%. Our results suggest that tau spreads through functional connections, rather than structural connections or simple diffusion.

Comparative interactome mapping of Tau‐protein in classical and rapidly progressive Alzheimer's disease identifies subtype‐specific pathways

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Deep multilayer brain proteomics identifies molecular networks and Netrin‐1 accumulation in Alzheimer’s disease progression: Genetics/omics and systems biology

Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

Axonal Tau sorting depends on the PRR2 domain and 0N4R-specific interactions hint at distinct roles of Tau isoforms in synaptic plasticity

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Tau protein profiling in tauopathies: a human brain study

Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

O4‐12‐03: Brain Phosphoproteome Network Analysis Discriminates Alzheimer's Disease from Other Tauopathies

Understanding the complex interplay between tau, amyloid and the network in the spatiotemporal progression of Alzheimer’s Disease

Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery

Tau interactome mapping reveals dynamic processes in synapses and mitochondria associated with neurodegenerative disease

Selective vulnerability and resilience to Alzheimer’s disease tauopathy as a function of genes and the connectome

Remote Associations Between Tau and Cortical Amyloid-β Are Stage-Dependent

Proteomic Landscape of Alzheimer's Disease: Novel Insights into Pathogenesis and Biomarker Discovery

Tau protein spreads through functionally connected neurons in Alzheimer’s disease

A Map of Transcriptomic Signatures of Different Brain Areas in Alzheimer's Disease